Form 8-K - Current report:
SEC Accession No. 0001193125-25-133745
Filing Date
2025-06-03
Accepted
2025-06-03 07:00:19
Documents
13
Period of Report
2025-06-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d843671d8k.htm   iXBRL 8-K 33877
2 EX-3.1 d843671dex31.htm EX-3.1 5867
  Complete submission text file 0001193125-25-133745.txt   164287

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20250602.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20250602_lab.xml EX-101.LAB 19482
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20250602_pre.xml EX-101.PRE 12149
15 EXTRACTED XBRL INSTANCE DOCUMENT d843671d8k_htm.xml XML 3974
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 251017133
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)